- Home
- PODC vs MRSN Comparison
PODC vs MRSN Comparison
Compare PODC & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PODC
- MRSN
- Stock Information
- Founded
- PODC 2013
- MRSN 2001
- Country
- PODC United States
- MRSN United States
- Employees
- PODC N/A
- MRSN N/A
- Industry
- PODC
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- PODC
- MRSN Health Care
- Exchange
- PODC Nasdaq
- MRSN Nasdaq
- Market Cap
- PODC 44.1M
- MRSN 40.7M
- IPO Year
- PODC N/A
- MRSN 2017
- Fundamental
- Price
- PODC $1.94
- MRSN $0.32
- Analyst Decision
- PODC Strong Buy
- MRSN Buy
- Analyst Count
- PODC 1
- MRSN 3
- Target Price
- PODC $5.00
- MRSN $4.00
- AVG Volume (30 Days)
- PODC 23.7K
- MRSN 2.3M
- Earning Date
- PODC 05-29-2025
- MRSN 05-15-2025
- Dividend Yield
- PODC N/A
- MRSN N/A
- EPS Growth
- PODC N/A
- MRSN N/A
- EPS
- PODC N/A
- MRSN N/A
- Revenue
- PODC $49,729,000.00
- MRSN $40,497,000.00
- Revenue This Year
- PODC $20.67
- MRSN N/A
- Revenue Next Year
- PODC $19.09
- MRSN N/A
- P/E Ratio
- PODC N/A
- MRSN N/A
- Revenue Growth
- PODC 22.98
- MRSN 9.88
- 52 Week Low
- PODC $1.10
- MRSN $0.26
- 52 Week High
- PODC $2.85
- MRSN $3.50
- Technical
- Relative Strength Index (RSI)
- PODC 54.47
- MRSN 41.87
- Support Level
- PODC $1.71
- MRSN $0.35
- Resistance Level
- PODC $1.99
- MRSN $0.44
- Average True Range (ATR)
- PODC 0.19
- MRSN 0.04
- MACD
- PODC 0.01
- MRSN -0.00
- Stochastic Oscillator
- PODC 38.75
- MRSN 8.48
About PODC PodcastOne Inc.
PodcastOne Inc is a podcast platform and publisher that makes its content available to audiences via all podcasting distribution platforms, including its website, its PodcastOne app, Apple Podcasts, Spotify, Amazon Music, and more.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.